INAC%252520Vendor%252520Prospectus%25252
INAC-01_edited.png

The Idaho Neuroscience of Addiction Coalition was founded in 2018. 

"The application of neuroscientific technologies in humans and laboratory animals has led to remarkable advances in our understanding of the neurobiological underpinnings of drug reinforcement and addiction. As a result, addiction, which has been viewed historically as a “moral deficiency,” is being increasingly regarded as a chronic relapsing disorder characterized by an urge to consume drugs and by the progressive loss of control over, and escalation in, drug intake despite repeated (unsuccessful) attempts to resist doing it."

THE NEUROSCIENCE OF DRUG REWARD AND ADDICTION

Nora D. Volkow, Michael Michaelides, and Ruben Baler

https://journals.physiology.org/doi/pdf/10.1152/physrev.00014.2018

"Addiction, the most severe form of substance use disorder, is a chronic brain disorder molded by strong biosocial factors that has devastating consequences to individuals and to society. Our understanding of substance use disorder has advanced significantly over the last 3 decades in part due to major progress in genetics and neuroscience research and to the development of new technologies, including tools to interrogate molecular changes in specific neuronal populations in animal models of substance use disorder, as well as brain imaging devices to assess brain function and neurochemistry in humans."

Neuroscience of Addiction: Relevance to Prevention and Treatment

Nora D. Volkow, M.D., Maureen Boyle, Ph.D.

https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2018.17101174

"The burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance."

GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder: a systematic review and metaanalysis protocol

Caroul Chawar1,2, Alannah Hillmer1,2, Stephanie Sanger3 , Alessia D’Elia1,2, Balpreet Panesar1,2, Lucy Guan2,4, Dave Xiaofei Xie2,4, Nandini Bansal2,4, Aamna Abdullah2,4, Flavio Kapczinski2 , Guillaume Pare5,6, Lehana Thabane5,6,7 and Zainab Samaan2*

https://systematicreviewsjournal.biomedcentral.com/track/pdf/10.1186/s13643-020-01461-z.pdf